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Convection-enhanced delivery (CED) with various drug 
carrier systems has recently emerged as a novel chemo-
therapeutic method to overcome the problems of cur-
rent chemotherapies against brain tumors. Polymeric 
micelle systems have exhibited dramatically higher in 
vivo antitumor activity in systemic administration. This 
study investigated the effectiveness of CED with poly-
meric micellar doxorubicin (DOX) in a 9L syngeneic rat 
model. Distribution, toxicity, and efficacy of free, lipo-
somal, and micellar DOX infused by CED were evalu-
ated. Micellar DOX achieved much wider distribution in 
brain tumor tissue and surrounding normal brain tissue 
than free DOX. Tissue toxicity increased at higher doses, 
but rats treated with micellar DOX showed no abnormal 
neurological symptoms at any dose tested (0.1–1.0 mg/
ml). Micellar DOX infused by CED resulted in prolonged 
median survival (36 days) compared with free DOX (19.6 
days; p 5 0.0173) and liposomal DOX (16.6 days; p 5 
0.0007) at the same dose (0.2 mg/ml). This study indi-
cates the potential of CED with the polymeric micelle 
drug carrier system for the treatment of brain tumors. 
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Convection-enhanced delivery (CED) is a promis-ing local delivery technique using bulk flow to deliver low-molecular-weight and macromolecu-
lar drugs directly to targeted sites in clinically significant 
volumes of tissue and to achieve wider volumes of dis-
tribution compared with simple diffusion techniques.1 
CED bypasses the blood–brain barrier that prevents 
most anticancer drugs from penetrating into the CNS, 
delivers a high concentration of therapeutic agents to the 
targeted site, and minimizes systemic exposure, result-
ing in fewer side effects.1 Many antineoplastic drugs,2–5 
including immunotoxins and boronated drugs,6,7 have 
been administered using CED, with promising outcomes 
in animal studies. The problems include rapid drug clear-
ance from the tumor interstitium,6 no selective accumu-
lation in targeted tissues,7 and brain damage caused by 
highly cytotoxic agents with extensive distribution in 
the CNS.2–5 Consequently, novel drug delivery systems 
are necessary to achieve the highest possible therapeutic 
index against tumor cells over healthy neuronal cells.8,9
Incorporation or attachment of low-molecular-weight 
anticancer drugs into drug carriers with high molecular 
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weight and hydrophilicity may provide substantial inhi-
bition of drug clearance from the tumor interstitium, in 
contrast to low-molecular-weight drugs that are cleared 
very rapidly by active transport via proteins such as 
P-glycoprotein as well as by passive diffusive transport 
through the lipid bilayer of the endothelium. The drug 
carrier systems also offer the advantage of sustained drug 
release, as prolonged exposure time is more important 
than the peak concentration factor for many anticancer 
drugs. However, only liposomes have been studied as 
drug carriers in combination with CED.8–12
Polymeric micelles are an assembly of synthetic poly-
mers, most typically block copolymers with both hydro-
phobic and hydrophilic blocks. Polymeric micelle carrier 
systems were first studied for targeting solid tumors by 
intravenous injection.13–16 Polymeric micelle carrier sys-
tems are electrically neutral and so have the so-called 
stealth property that evades rapid clearance at the reticu-
loendothelial systems,17 which substantially improves 
targeting of murine solid tumors due to the enhanced 
permeability and retention effect that depends on the 
hyperpermeable vasculature and absence of effective 
lymphatic drainage that prevents efficient clearance of 
micromolecules in the solid tumor tissues.18 Polymeric 
micelles incorporating micellar doxorubicin (DOX) were 
initially developed to enhance the safety and efficacy 
of conventional DOX.13 Various micelle-encapsulated 
cytotoxic agents are currently undergoing clinical evalu-
ation of systemic administration, including DOX,9 
paclitaxel,19 cisplatin,20 camptothecin,21 and the camp-
tothecin derivative SN-38.22 In contrast, local delivery 
of polymeric micelle systems for the treatment of brain 
tumors remains relatively unexplored.
The present study evaluated the therapeutic possibili-




Doxorubicin hydrochloride was purchased from Mer-
cian Corp. (Tokyo, Japan). Stock solutions of free DOX 
were prepared by diluting DOX in dimethyl sulfoxide 
to a concentration of 50 mg/ml. The infusion solution 
of free DOX was made by diluting the stock solution 
with phosphate-buffered saline (PBS). Liposomal DOX 
(Doxil) was obtained from Alza Pharmaceuticals (Moun-
tain View, CA, USA). Micellar DOX was prepared by the 
previously reported method in a slight modification only 
in high-performance liquid chromatography (HPLC) 
analysis conditions.14–16 In brief, DOX was chemically 
conjugated to the aspartic acid residue of poly(ethylene 
glycol)-b-poly(aspartic acid) block copolymer. The 
hydrophobicity of the DOX-conjugated poly(aspartic 
acid) block results in the formation of a polymeric micelle 
structure. This conjugate block copolymer was used to 
form empty polymeric micelles in this study because this 
type of micelle does not contain unbound DOX that is 
important in cytotoxic activity. Free DOX was incorpo-
rated into empty polymeric micelles to form pharma-
cologically active polymeric micelles that contain free 
DOX in the micelle inner core. The poly(ethylene glycol) 
block had a molecular weight of 12 kDa and contained 
22 aspartic acid units as determined by 1H-nuclear mag-
netic resonance spectrum in D2O. DOX was chemically 
conjugated to 59% of the aspartic acid residues, and the 
micelles contained 13 wt% free DOX. The amounts 
of the chemically conjugated DOX and the physically 
entrapped DOX were determined by a reverse-phase 
HPLC according to methods previously reported.15,16 
The empty polymeric micelles (DOX was not physically 
entrapped) chemically conjugated DOX molecules to 
68% of the aspartic acid residues. The infusion solution 
for micellar DOX, PBS, had no toxicity when 20 μl was 
infused by CED (preliminary data not shown).
Tumor Cell Lines
9L gliosarcoma cells (American Type Culture Collection, 
Rockville, MD, USA) were maintained as monolayers in 
a complete medium consisting of Eagle’s minimal essen-
tial medium supplemented with 10% fetal calf serum, 
nonessential amino acids, and 100 U/ml penicillin G. 
Cells were cultured at 37°C in a humidified atmosphere 
consisting of 95% air and 5% CO2.
Animals and Intracranial Syngeneic Transplantation 
Technique
All protocols utilized in the animal studies were approved 
by the Institute for Animal Experimentation of Tohoku 
University Graduate School of Medicine. Male Fischer 
344 rats weighing 150–200 g and normal male Sprague-
Dawley rats weighing approximately 150–200 g were 
purchased from Charles-River Laboratories (Charles-
River Japan Inc., Tsukuba, Japan). For the intracranial 
syngeneic tumor model, 9L gliosarcoma cells were har-
vested by trypsinization, washed once with Hanks’ bal-
anced salt solution without Ca21 and Mg21 (HBSS), and 
resuspended in HBSS for implantation. Cells (5 3 105) 
in 10 μl HBSS were implanted into the striatal region of 
the rat brains as follows. The rats under deep isoflurane 
anesthesia were placed in a small-animal stereotactic 
frame (David Kopf Instruments, Tujunga, CA, USA). A 
sagittal incision was made to expose the cranium, fol-
lowed by a burr hole in the skull at 0.5 mm anterior 
and 3 mm lateral from the bregma using a small dental 
drill. Cell suspension (5 μl) was injected over 2 min at a 
depth of 4.5 mm from the brain surface; after a 2-min 
wait, another 5 μl was injected over 2 min at a depth 
of 4.0 mm, and after a final 2-min wait, the needle was 
removed and the wound was sutured.
CED Infusion
CED of PBS, free DOX, liposomal DOX, and micellar 
DOX was performed as described previously.9,11 The 
infusion system consisted of a reflux-free step design 
infusion cannula23 connected to a loading line (contain-
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The rats in each group were euthanized 3 weeks after the 
CED treatment, and their brains were removed, fixed, 
cut into sections (5 μm), and stained with hematoxylin 
and eosin (H&E).
Survival Studies
Fifty-two Fischer 344 rats with 9L tumor cells were 
randomly assigned to four groups: (1) the control group 
that received PBS (20 μl solution; n 5 17), (2) free DOX 
(0.2 mg/ml DOX in 20 μl solution; n 5 10), (3) lipo-
somal DOX (20 μl solution containing 0.2 mg/ml DOX 
equivalent; n 5 14), and (4) micellar DOX (20 μl solu-
tion containing 0.2 mg/ml physically entrapped free 
DOX equivalent; n 5 11). Seven days after tumor cell 
implantation, a single CED infusion was performed for 
each group. Rats were monitored daily for survival and 
general health, and weekly for weight. The study was 
terminated 90 days after tumor implantation. The sur-
viving animals were euthanized and their brains stained 
with H&E. Survival was expressed as a Kaplan-Meier 
curve. Survival between the treatment groups was com-
pared with a log-rank test.
Results
Evaluation of Distribution of Micellar DOX  
in Normal Rodent CNS
Compared with free DOX (Fig. 1a), intrastriatal admin-
istration of liposomal DOX (Fig. 1b), micellar DOX (Fig. 
1c), and empty polymeric micelles (Fig. 1d) via CED (20 
μl volume) produced extensive and diffuse distribution 
in the striatum. The mean volumes of distribution of free 
DOX, liposomal DOX, micellar DOX, and empty poly-
meric micelles in normal rat brains were 13.91 6 1.23 mm3 
(range, 12.12–15.32 mm3), 64.25 6 7.83 mm3 (54.76–
77.40 mm3), 60.54 6 5.71 mm3 (54.40–64.25 mm3), 
and 54.74 6 4.39 mm3 (50.30–58.97 mm3), respectively 
(Fig. 1e). A significant difference was observed between 
free DOX and micellar DOX (p 5 0.009), but not between 
liposomal DOX and micellar DOX (p 5 0.465).
Evaluation of Distribution of Micellar DOX  
in Rats with 9L Tumors
Examination of representative rat brain sections at 
1-mm intervals confirmed successful formation of the 
tumor tissue. Fluorescent detection of DOX in the same 
sections revealed poor distribution of free DOX (Fig. 2a) 
but distribution of micellar DOX over almost the entire 
tumor mass, including the surrounding tumor margins 
(Fig. 2b). The findings were consistent in all four rats 
examined from this group.
Toxicity of Micellar DOX in Normal Rodent CNS
Rats euthanized 3 weeks after infusion with 0.2 (Fig. 3a, 
center), 0.4 (Fig. 3a, right), and 1.0 (data not shown) mg/
ml micellar DOX showed tissue damage at the infusion 
DOX solutions) and an olive oil infusion line. A 1-ml 
syringe (filled with oil) was mounted onto a microinfu-
sion pump (BeeHive; Bioanalytical Systems, West Lafay-
ette, IN, USA) to regulate the flow of fluid through the 
system. Based on chosen coordinates, the infusion can-
nula was mounted onto a stereotactic holder and guided 
to the target region of the brain through burr holes made 
in the skull (see below). The infusion rates followed the 
following ascending pattern to deliver the total 20-μl 
infusion volume: 0.2 μl/min (15 min) 1 0.5 μl/min (10 
min) 1 0.8 μl/min (15 min).
Evaluation of Distribution of Micellar DOX  
in Normal Rodent CNS
Normal Sprague-Dawley rats (five rats in each group) 
received CED using free DOX (2 mg/ml DOX in 20 μl 
solution), liposomal DOX (20 μl solution containing 
2 mg/ml DOX equivalent), and micellar DOX (20 μl 
solution containing 2 mg/ml physically entrapped DOX 
and 4.3 mg/ml chemically conjugated DOX equivalent), 
and empty polymeric micelles (20 μl solution contain-
ing 7.9 mg/ml chemically conjugated DOX equivalent) 
and were euthanized immediately after CED. The brains 
were harvested, frozen in isopentane chilled in dry ice, 
and cut into serial coronal sections (25 μm) with a cry-
ostat. DOX fluoresces under UV illumination, so the 
areas of distribution could be visualized by fluorescence 
microscopy and captured with a charged-coupled device 
camera with a fixed aperture. The empty polymeric 
micelles were also fluorescent in a similar manner to 
the micellar DOX, since the empty polymeric micelles 
contained chemically conjugated DOX molecules that 
were almost equivalent in their fluorescent behavior to 
physically entrapped DOX of the micellar DOX. The 
volume of distribution was analyzed with a Macintosh-
based image-analysis system (NIH Image 1.62; NIH, 
Bethesda, MD, USA) as described previously.24
Evaluation of Distribution of Micellar DOX in Rats 
with 9L Intracranial Tumors
Fischer 344 rats (four rats in each group) with 9L intra-
cranial tumors received CED using micellar DOX and 
free DOX (20 μl solution containing 2 mg/ml DOX 
equivalent) 7 days after tumor cell implantation. Rats 
were euthanized immediately after CED. The brains 
were harvested, frozen in isopentane chilled in dry 
ice, and cut into serial coronal sections (25 μm) with a 
cryostat.
Toxicity Tests of Micellar DOX
Normal Sprague-Dawley rats (five rats in each group) 
received a single CED infusion of free DOX, liposomal 
DOX, micellar DOX, and empty polymeric micelles (20 
μl solutions containing 0.1, 0.2, 0.4, or 1.0 mg/ml free 
DOX equivalent). Rats were monitored daily for sur-
vival and general health (alertness, grooming, feeding, 
excreta, skin, fur, mucous membrane conditions, ambu-
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site but did not develop neurological symptoms. Rats that 
received 0.1 mg/ml micellar DOX (Fig. 3a, left) showed 
negligible tissue damage and survived without neurolog-
ical symptoms. Rats infused with 0.1 (Fig. 3b, left) and 
0.4 (Fig. 3b, right) mg/ml free DOX showed tissue dam-
age without neurological symptoms. Rats infused with 
0.1 (Fig. 3c, left) and 0.4 (Fig. 3c, right) mg/ml liposomal 
DOX revealed less tissue damage. Therefore, the maxi-
mum tolerated dose of micellar DOX was established 
as below 0.2 mg/ml. Rats treated with empty polymeric 
micelles showed no toxicity (data not shown).
Antitumor Efficacy of Micellar DOX Treatment
Rats in the control group (Fig. 4a) were all euthanized 
at 10–21 days after tumor cell implantation due to neu-
rological symptoms indicative of tumor progression. 
Median survival for this group was 16.9 days. Rats that 
received CED of free DOX (Fig. 4b) were euthanized 
due to neurological complications indicative of tumor 
progression at 16–33 days after tumor cell implanta-
tion. Median survival for this group was 19.6 days. 
Rats that received CED of 0.2 mg/ml liposomal DOX 
Fig. 1. Evaluation of distribution of micellar DOX in normal rats. Sequential hematoxylin and eosin-stained sections 25 μm thick at 1-mm 
intervals reveal the tumor (top). The sections were examined with a fluorescence microscope to detect the fluorescence generated by DOX 
(bottom). Compared with free DOX (a), liposomal DOX (b), micellar DOX (c), and empty polymeric micelles (d) produced extensive and dif-
fuse distribution in the striatum. (e) Median values and the 75% quartiles of volume distribution (Vd) after infusion of free DOX, liposomal 
DOX, micellar DOX, and empty polymeric micelles. The difference in the distribution between free DOX and micellar DOX was statistically 
significant (p 5 0.009, as analyzed by Mann-Whitney U-test), but differences in the distribution among liposomal DOX, micellar DOX, 
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(Fig. 4c) were euthanized at 10–27 days after tumor cell 
implantation. Median survival for this group was 16.6 
days. Formation of large tumors was verified in all rats 
euthanized in these three groups. Nine of the 11 rats 
that received CED of 0.2 mg/ml micellar DOX (Fig. 4d) 
were euthanized at 15–43 days after tumor cell implan-
tation due to neurological symptoms, but the other two 
rats survived until termination of the study at 90 days. 
Median survival for this group was 36 days. The sur-
vival time after CED with 0.2 mg/ml micellar DOX was 
significantly greater than after CED with free DOX (p 5 
0.0173) or liposomal DOX (p 5 0.0007). Although the 
rats in the control group had histological signs of tumor 
in the brain (Fig. 4e), only a small amount of brain dam-
age was observed in the surviving two rats that received 
micellar DOX (Fig. 4f).
Discussion
The present study found that liposomal DOX and micel-
lar DOX had similar extensive distributions in the nor-
mal rat brain and were far more widely distributed than 
free DOX. This study also showed distribution of micel-
lar DOX over almost the entire tumor area, including 
the margins. CED distribution in CNS is significantly 
increased if the infusate is more hydrophilic, which 
implies less tissue affinity.9,11 Furthermore, polyethyl-
ene glycol encapsulation provides steric stabilization, 
reduces surface charge, and achieves better distribution 
in brain.9 The poorer brain distribution observed with 
hydrophobic or cationic infusate can be completely over-
come by polyethylene glycol encapsulation.9
Delivery pattern of micellar DOX was expected to 
avoid the high peak concentrations of free DOX poten-
tially associated with toxicity.13,25 However, evaluation 
of the toxicity in normal rat brain found that 0.2 mg/ml 
micellar DOX caused a lesion similar to that caused by 
0.2 mg/ml free DOX, although no difference in toxicity 
was observed. In contrast, 0.2 mg/ml liposomal DOX 
showed no toxicity, which might reflect poor release 
of the cytotoxic agent. These findings indicate that the 
safety of micellar DOX in CED could be achieved by 
optimization of drug release to avoid the high concen-
trations that trigger nonspecific toxicity. Micellar sys-
tems, relative to  liposomal systems, offer the advantage 
of adjustable drug release based on the properties of the 
Fig. 2. Evaluation of distribution of micellar DOX in rats with 9l tumors. Seven days after tumor cell implantation, 2 mg/ml free DOX or 
micellar DOX was infused intratumorally by CED. Rats were euthanized 1 h after CED, and the brains were sectioned on a cryostat. Sequen-
tial hematoxylin and eosin-stained sections 25 μm thick at 1-mm intervals reveal the tumor (top). The same sections were examined with 
a fluorescence microscope to detect the fluorescence generated by DOX (bottom). Free DOX had poor distribution (a), whereas micellar 
DOX achieved coverage of almost the entire tumor mass, including the surrounding tumor margins (b). The findings were consistent in all 
four animals.
Fig. 3. Toxicity at different drug concentrations. (a) Rats infused 
with 0.1 mg/ml micellar DOX (left) survived without neurologi-
cal symptoms and negligible tissue damage. Rats infused with 0.2 
(center) and 0.4 (right) mg/ml micellar DOX showed significant 
tissue damage at the infusion site but did not develop neuro-
logical symptoms. (b) Rats infused with 0.1 (left) and 0.4 (right) 
mg/ml free DOX demonstrated tissue damage without neurologi-
cal symptoms. (c) Rats infused with 0.1 (left) and 0.4 (right) mg/
ml liposomal DOX revealed less tissue damage, which might reflect 
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micelle inner core,13–16,25 but further development of 
micellar systems for use with CED is required.
The present study found that CED with 0.2 mg/
ml micellar DOX significantly prolonged survival in 
rats with intracranial 9L glioma, compared with CED 
with 0.2 mg/ml free DOX and liposomal DOX, which 
is known to show efficient targeting to solid tumors by 
systemic injection like micellar DOX. Liposomal DOX 
does not release DOX efficiently because of excessive 
stable incorporation in the lipid bilayer,17 which prob-
ably accounts for the absence of significant increase in 
efficacy against rapidly growing 9L syngeneics compared 
with free DOX.
The polymeric micelle system has three advantages 
as a drug carrier compared with the liposome drug car-
rier. First, polymeric micelles can incorporate hydro-
phobic drugs into the inner core phase, to high loadings 
such as 30 wt% without losing targeting potential. In 
contrast, the liposomal system may easily lose target-
ing ability at high drug loadings because the hydropho-
bic drug must be incorporated into the very thin lipid 
bilayer. Second, polymers may be based on many chemi-
cal structures with various physical characteristics such 
as crystalline and glassy, so the drug release rate can 
be adjusted in a very wide range from minutes to days. 
Finally, micelle diameters can be tightly controlled in a 
range from 10 nm to 100 nm, choosing the appropriate 
chemical structures and chain lengths of polymers. The 
polymeric micelle can obtain this size control among 
many types of drug carriers. Consequently, the micelle 
system has high potential for specific adjustment to the 
treatment of various CNS tumors by CED infusion. Fur-
thermore, micellar systems could be used in monitoring 
drug distribution by using micelles containing a marker 
for imaging.23,24 The present findings indicate the sig-
nificant potential of micellar drugs for the treatment of 
malignant glioma.
Fig. 4. Survival study. (a–d) Outcome for rats bearing 9l tumors 
with single CED infusion of saline (a), free DOX (b), liposomal DOX 
(c), and micellar DOX (d). Seven days after tumor implantation 
within the brain, rats were treated with 0.2 mg/ml of each agent. 
Median survival for the groups were 16.9 days (a), 19.6 days (b), 
16.6 days (c), and 36 days (d). Statistically significant differences 
were observed between free DOX and micellar DOX (p 5 0.0173) 
and between liposomal DOX and micellar DOX (p 5 0.0007). (e 
and f) Histological examination found tumor formation in the con-
trol group (e) and brain damage in rats receiving micellar DOX (f).
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